Zetta Genomics has raised £2.5 million ($3.4 million) in new seed funding.
Zetta Genomics, a spin out from the University of Cambridge in the United Kingdom, has raised £2.5 million ($3.4 million) in new seed funding, it was revealed in a Feb. 1, 2022 press release. With the funds raised, the company will invest in its XetaBase platform, which is a transformational genomic data management technology for the discovery and delivery of precision medicine at scale.
“Zetta Genomics re-imagines data to deliver a dynamic platform fit for the fast-emerging, fast-scaling, multi-petabyte environment,” said Ignacio Medina, Zetta Genomics founder, in the press release. “In liberating genomic data—placing its power into the hands of researchers and clinicians—we will drive precision medicine’s transformation into mainstream healthcare and life-changing patient benefit.”
“Genomic medicine has enjoyed explosive growth in the past five years, but this is set to be eclipsed in the next decade,” added Marc Subriats, partner, Nina Capital—a lead investor—in the press release. “XetaBase is an enabling technology—empowering virtually every research field and clinical application. As genomic sequencing moves from the hundreds of thousands to the hundreds of millions, Nina Capital is confident that Zetta Genomics’ growth will both drive and be driven by rapid advances in precision medicine.”
“Cambridge Enterprise creates and invests in companies, built on University of Cambridge research, that can have a huge positive impact on society,” said Elaine Loukes, investment director at University of Cambridge Enterprise—an investor in Zetta Genomics—in the press release. “From our first meeting it was clear that Ignacio had developed something incredibly special. Zetta’s technology helps researchers and clinicians fully exploit genomic data, speeding the delivery of precision medicine across the world.”
Source: Zetta Genomics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.